RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects

Summary

This is a Phase 1, multicentric, open-label,two arms to assess and compare the effect of single oral administration of MD1003 on the pharmacokinetic parameters in renal impaired patients and healthy subjects with normal renal function. The planned enrollment is 36 subjects (18 impaired patients and 18 healthy subjects).

Timeline

Start

2019-10-09

Primary completion

2020-03-17

Completion

2020-03-17

Outcome

Outcome not reported

Stopped: “Due to other phase 3 trial failure to meet primary endpoint”

Drugs

Indications